buy

Alnylam Pharmace. buy Barclays PLC

Alnylam Pharmace.

Start price

€221.10

/ 50%

Target price

25.06.25

Performance (%)

End price

€277.90

Summary

This prediction ended on with a price of €277.90. The prediction had a final performance of . Barclays_PLC has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Barclays_PLC has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Feedback

Performance without dividends (%)

Name	1w	1m	1y
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Barclays_PLC for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 271.881

Change

Ends at

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Barclays PLC from $236.00 to $291.00. They now have an "overweight" rating on the stock.

Ratings data for ALNY provided by MarketBeat

Barclays PLC